EP1340749A4 - Isoxazole derivatives - Google Patents

Isoxazole derivatives

Info

Publication number
EP1340749A4
EP1340749A4 EP01983808A EP01983808A EP1340749A4 EP 1340749 A4 EP1340749 A4 EP 1340749A4 EP 01983808 A EP01983808 A EP 01983808A EP 01983808 A EP01983808 A EP 01983808A EP 1340749 A4 EP1340749 A4 EP 1340749A4
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
hydrogen
group
general formula
isoxazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01983808A
Other languages
German (de)
French (fr)
Other versions
EP1340749A1 (en
Inventor
Yu Momose
Tsuyoshi Maekawa
Tomoko Asakawa
Nozomu Sakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP1340749A1 publication Critical patent/EP1340749A1/en
Publication of EP1340749A4 publication Critical patent/EP1340749A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Abstract

Compounds of the general formula (I) or their salts or prodrugs have excellent insulin secretion promoting and blood sugar decreasing effects and are lowly toxic, thus being useful as drugs, particularly preventive and therapeutic agents for diabetes and diabetic complication, wherein one of R?1 and R2¿ is hydrogen or a substituent and the other is an optionally substituted cyclic group; W is a free valency or a divalent aliphatic hydrocarbon group; and Y is a group represented by the general formula: -OR3 (wherein R3 is hydrogen, optionally substituted hydrocarbyl, an optionally substituted heterocyclic group, or optionally substituted acyl) or carboxyl which may be converted into an ester or an amide.
EP01983808A 2000-11-17 2001-11-16 Isoxazole derivatives Withdrawn EP1340749A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000350869 2000-11-17
JP2000350869 2000-11-17
PCT/JP2001/010001 WO2002040458A1 (en) 2000-11-17 2001-11-16 Isoxazole derivatives

Publications (2)

Publication Number Publication Date
EP1340749A1 EP1340749A1 (en) 2003-09-03
EP1340749A4 true EP1340749A4 (en) 2007-09-05

Family

ID=18824021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01983808A Withdrawn EP1340749A4 (en) 2000-11-17 2001-11-16 Isoxazole derivatives

Country Status (5)

Country Link
US (2) US7022725B2 (en)
EP (1) EP1340749A4 (en)
AU (1) AU2002215218A1 (en)
CA (1) CA2429426A1 (en)
WO (1) WO2002040458A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546429B2 (en) 2003-07-11 2013-10-01 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR102083040B1 (en) 2011-12-22 2020-02-28 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057215A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Neurotrophic factor production/secretion accelerator
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
FR2851769B1 (en) * 2003-02-28 2006-06-23 NOVEL LXRs RECEPTOR-MODULATING LIGANDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN MEDICINE AND COSMETICS
WO2004076418A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MXPA06000554A (en) * 2003-07-14 2006-07-03 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.
WO2005012269A1 (en) 2003-08-05 2005-02-10 Ajinomoto Co., Inc. Novel azole compound
ES2278346T3 (en) 2003-08-20 2007-08-01 Eli Lilly And Company COMPOUNDS, PROCEDURES AND FORMULATIONS FOR ORAL SUPPLY OF A PEPTIDE COMPOUND (LPG) -1 OF THE TYPE OF GLUCAGON OR AN AGONISTIC PEPTIDE (LPG) -4 OF THE RECEIVER 4 OF MELACORTINE (MC4).
BRPI0413676B8 (en) * 2003-08-20 2021-05-25 Lilly Co Eli oxazole and oxadiazole derivative compounds and pharmaceutical compositions useful for the oral delivery of glucagon-like peptide compound-1 (glp-1) or melatonin receptor agonist type 4 peptide (mc4)
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP2813225B1 (en) * 2004-09-24 2017-12-13 University of Maryland, Baltimore Method of treating organophosphorous poisoning
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
BRPI0809607A2 (en) * 2007-04-02 2014-09-30 Theracos Inc COMPOUND, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION, AND METHOD FOR TREATING A DISEASE
JP5823125B2 (en) * 2007-10-23 2015-11-25 ウェルズ ファーゴ バンク ナショナル アソシエイション Hydroxyapatite targeted multi-arm polymer and conjugates made from this polymer
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
WO2010017132A1 (en) * 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN102177147A (en) * 2008-08-22 2011-09-07 泰拉科斯有限公司 Processes for the preparation of SGLT2 inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
WO2012138797A1 (en) 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN106518845B (en) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 Kynurenin -3- monooxygenase inhibitor, pharmaceutical composition and its application method
KR20140072037A (en) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
JP6564380B2 (en) 2013-09-20 2019-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Compounds for treating prostate cancer
CN105611920B (en) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 Preparation of hydroxy-diphenylmethane derivatives
CN114588157A (en) 2014-07-17 2022-06-07 Chdi基金会股份有限公司 Methods and compositions for treating HIV-related disorders
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
NZ738862A (en) 2015-06-22 2023-12-22 Arena Pharm Inc Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6678779B2 (en) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド FXR (NR1H4) modulating compound
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EP4122464A1 (en) 2017-03-28 2023-01-25 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
EA202191566A1 (en) 2019-01-15 2021-11-01 Джилид Сайенсиз, Инк. CONNECTIONS MODULATING FXR (NR1H4)
EP3927683A1 (en) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Solid forms of fxr agonists
GB2609003A (en) * 2021-07-15 2023-01-25 Univ Nottingham Trent Compounds and pharmaceutical compositions for the treatment of metabolic disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752818A (en) * 1969-04-29 1973-08-14 Bayer Ag Sulphonyl ureas and sulphonyl semicarbazides containing heterocyclic acyl amino groups and their production
US4243406A (en) * 1978-12-26 1981-01-06 Monsanto Company 5-Aryl-4-isoxazolecarboxylate-safening agents
EP0326108A1 (en) * 1988-01-26 1989-08-02 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
WO1997028160A1 (en) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
WO2000064876A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5942670B2 (en) 1977-09-09 1984-10-16 大鵬薬品工業株式会社 β-(3-methyl-5-isoxazolyl)acrylic acid amide derivative and method for producing the same
JPS6212776A (en) 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk Rhodanine derivative
DE4408084A1 (en) 1994-03-10 1995-09-14 Hoechst Ag 3,5-disubstituted and 3,4,5-trisubstituted 2-isoxazolines and isoxazoles, processes for their preparation and their use as medicaments
ATE236890T1 (en) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co OXYGEN OR SULFUR CONTAINING 5-MEMBED HETEROAROMATIC DERIVATIVES AS FACTOR XA INHIBITORS
ATE207065T1 (en) 1997-08-08 2001-11-15 Aventis Pharma Gmbh CRYSTAL FORM OF N-(4-TRIFLUORMETHYLPHENYL)-5-METHYLISOXAZOLE-4-CARBONIC ACID AMIDE
WO2000008001A1 (en) 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
ID30237A (en) * 1998-12-24 2001-11-15 Metabasis Therapeutics Inc COMBINATION OF FBPASE OBSTACLES AND INSULIN PLANTS FOR DIABETES TREATMENT

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752818A (en) * 1969-04-29 1973-08-14 Bayer Ag Sulphonyl ureas and sulphonyl semicarbazides containing heterocyclic acyl amino groups and their production
US4243406A (en) * 1978-12-26 1981-01-06 Monsanto Company 5-Aryl-4-isoxazolecarboxylate-safening agents
EP0326108A1 (en) * 1988-01-26 1989-08-02 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
WO1997028160A1 (en) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
WO2000064876A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADACHI I ET AL: "ISOXAZOLES XIX SYNTHESIS AND CLEAVAGE REACTION OF SOME 3 4 DI SUBSTITUTED ISOXAZOLES", CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO), vol. 16, no. 1, 1968, pages 117 - 125, XP009087271, ISSN: 0009-2363 *
ANISIMOVA, GULYAEV, KARLINSKI, KIVMAN: "system of selecting antibiotics against infection with intracellular localization of infecting agents", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 31, no. 1, 1997, pages 9 - 11, XP009087278 *
FOSSA P ET AL: "5-substituted 4-isoxazoleacetic acids with analgesic activity.", FARMACO (SOCIETÀ CHIMICA ITALIANA : 1989) JAN 1994, vol. 49, no. 1, January 1994 (1994-01-01), pages 41 - 44, XP009087214, ISSN: 0014-827X *
PRUITT J R ET AL: "Isoxazolines and isoxazoles as factor Xa inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 8, April 2000 (2000-04-01), pages 685 - 689, XP004203474, ISSN: 0960-894X *
See also references of WO0240458A1 *
VENUGOPALAN B ET AL: "Antimalarial activity of new ethers and thioethers of dihydroartemisinin", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 30, no. 9, 1995, pages 697 - 706, XP004040197, ISSN: 0223-5234 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8546429B2 (en) 2003-07-11 2013-10-01 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
KR102083040B1 (en) 2011-12-22 2020-02-28 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof

Also Published As

Publication number Publication date
WO2002040458A1 (en) 2002-05-23
AU2002215218A1 (en) 2002-05-27
US20060084690A1 (en) 2006-04-20
CA2429426A1 (en) 2002-05-23
US7022725B2 (en) 2006-04-04
EP1340749A1 (en) 2003-09-03
US20040048908A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
EP1340749A4 (en) Isoxazole derivatives
WO2000058293A3 (en) Glucokinase activators
DK1642885T3 (en) Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for the treatment of inflammatory conditions of the gastrointestinal tract
NO944704L (en) Thiazolidine derivatives and pharmaceutical compositions containing them
DE69021472D1 (en) Pyrazole derivatives, processes for their preparation and pharmaceutical compositions containing them.
EP1698624A4 (en) Phenylpropanoic acid derivatives
CY1111310T1 (en) UNIONS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2004073611A3 (en) Compounds for the treatment of metabolic disorders
ATE358484T1 (en) ANTIDIABETIC DRUGS
MXPA05011592A (en) Compounds for the treatment of metabolic disorders.
NO975666L (en) Pyrrole derivatives and medical composition
EP1236719A4 (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
WO2004093806A3 (en) Compounds for the treatment of metabolic disorders
EP1182193A4 (en) Remedies for neuropathic pain
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
NO20014119D0 (en) Medication containing a sulfopyranosylacylglycerol derivative
NO20053464L (en) Medication for chronic pain
EP1914229A4 (en) Novel cercosporamide derivative
EP1398313A4 (en) Novel heterocyclic derivatives and medicinal use thereof
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
EP1295875A4 (en) Heterocyclic compounds
WO1998006400A3 (en) Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
ES2262504T3 (en) DERIVATIVES OF THE PYROGLUTAMIC ACID AND RELATED COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH THE VLA-4.
ATE275572T1 (en) MALTO-OLIGOSACCHARIDE DERIVATIVES AND THEIR APPLICATIONS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20070806

17Q First examination report despatched

Effective date: 20071120

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110823